Ivermectin has captured the imagination of a small group of global health scientists as one approach to solving the problem of residual transmission of malaria. This old, so-called wonder drug—an endectocide that targets both endoparasites and ectoparasites—was originally identified as a natural substance by Satoshi Ōmura of Kitasato Institute. The drug was further developed by William Campbell of Merck Labs as a potent anthelmintic, originally for use in veterinary health and targeting more than 20 species of helminth.
During the period in which SP was the first-line anti-malarial in Kenya, highly SP-resistant parasites emerged, including isolates harboring pfdhps mutations not previously observed there.
Control of severe malaria in an urban setting may be complicated by Plasmodium infections acquired elsewhere. Epidemiologic studies of urban malaria in low transmission settings should take travel history into account.